VBI Vaccines Inc. logo

VBIV

VBI Vaccines Inc.

$1.08

Earnings Summary

Revenue
$0.13Mn
Net Profits
$-21.25Mn
Net Profit Margins
-16868.25%

Highlights

Revenue:

VBI Vaccines Inc.’s revenue fell -58.14% since last year same period to $0.13Mn in the Q1 2022. On a quarterly growth basis, VBI Vaccines Inc. has generated 55.56% jump in its revenue since last 3-months.

Net Profits:

VBI Vaccines Inc.’s net profit fell -20.44% since last year same period to $-21.25Mn in the Q1 2022. On a quarterly growth basis, VBI Vaccines Inc. has generated -13.16% fall in its net profits since last 3-months.

Net Profit Margins:

VBI Vaccines Inc.’s net profit margin fell -187.72% since last year same period to -16868.25% in the Q1 2022. On a quarterly growth basis, VBI Vaccines Inc. has generated 27.26% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the VBI Vaccines Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-0.07
EPS Estimate Current Year
-0.07

Highlights

EPS Estimate Current Quarter:

VBI Vaccines Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.07 - a 12.5% jump from last quarter’s estimates.

EPS Estimate Current Year:

VBI Vaccines Inc.’s earning per share (EPS) estimates for the current year stand at -0.07.

Key Ratios

Key ratios of the VBI Vaccines Inc. post its Q1 2022 earnings

Earning Per Share (EPS)
-0.08
Return on Assets (ROA)
-0.2
Return on Equity (ROE)
-0.44
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

VBI Vaccines Inc.’s earning per share (EPS) fell -14.29% since last year same period to -0.08 in the Q1 2022. This indicates that the VBI Vaccines Inc. has generated -14.29% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. VBI Vaccines Inc.’s return on assets (ROA) stands at -0.2.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. VBI Vaccines Inc.’s return on equity (ROE) stands at -0.44.

Dividend Per Share (DPS):

VBI Vaccines Inc. declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.08
-0.08
0%

Company Information

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel under the name Sci-B-Vac® and completed its Phase 3 program in the U.S., Europe, and Canada in 2020; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Organisation
VBI Vaccines Inc.
Employees
130
Industry
Health Technology